Document is current
Any future updates will be listed below
-
Authors
Anzalone, Andrew V.
Gao, Xin D. http://orcid.org/0000-0003-2917-2060
Podracky, Christopher J.
Nelson, Andrew T.
Koblan, Luke W.
Raguram, Aditya
Levy, Jonathan M. http://orcid.org/0000-0002-8061-7953
Mercer, Jaron A. M.
Liu, David R. http://orcid.org/0000-0003-0346-5033
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (RM1 HG00949)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (U01 AI142756)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35 GM118062)
Howard Hughes Medical Institute (Liu investigatorship)
- License Information
-
More Information
Article History
Received: 1 July 2021
Accepted: 22 October 2021
First Online: 9 December 2021
Competing interests
: D.R.L. is a consultant and equity holder of Beam Therapeutics, Prime Medicine, Pairwise Plants and Chroma Medicine, companies that use genome editing or genome engineering technologies. A.V.A., C.J.P. and J.M.L. are currently employees at Prime Medicine. A.V.A., X.D.G., C.J.P., J.M.L. and D.R.L. have filed patent applications on twinPE and prime editing through the Broad Institute.
